12:09:55 EDT Sun 16 Jun 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Numinus Wellness Inc
Symbol NUMI
Shares Issued 316,455,100
Close 2024-05-29 C$ 0.065
Market Cap C$ 20,569,582
Recent Sedar Documents

Numinus approved for MDMA-assisted group therapy trial

2024-05-30 10:03 ET - News Release

Mr. Payton Nyquvest reports

NUMINUS WELLNESS RECEIVES HEALTH CANADA APPROVAL FOR STUDY INTO GROUP MODEL FOR MDMA-ASSISTED THERAPY

Health Canada has approved Numinus Wellness Inc.'s clinical trial application to examine the feasibility of a group model in MDMA-assisted (methylenedioxymethamphetamine) psychotherapy enrolling trainee practitioners as participants.

The study aims to enhance comprehension of the ideal number of therapists needed to administer MDMA-assisted psychotherapy group sessions effectively. Additionally, the trial offers eligible trainees the chance to develop core competencies through observing seasoned therapists conduct MDMA-assisted psychotherapy sessions and legally experience MDMA themselves in a therapeutic setting as healthy research subjects.

"We are pleased to have received approval for this study, which will be the first of its kind to investigate the viability of a group therapy model, establish the best methods for MDMA group therapy, and add to the existing research supporting its safe use," said Payton Nyquvest, Numinus founder and chief executive officer. "Considering the growing body of research into the potential benefits of MDMA for treating severe mental disorders, such as PTSD [posttraumatic stress disorder], it's essential that medical professionals enhance their understanding of how best to administer it in a clinical environment."

The clinical trial is formally titled "Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training."

"This study could greatly improve therapist understanding of the effects of MDMA, therapist skills and patient outcomes by offering practitioners a chance to gain crucial insights into different modalities of treatment," added Dr. Rick Doblin, PhD, an unpaid volunteer and Numinus strategic adviser. "This will become important should MDMA treatment for PTSD receive FDA [United States Food and Drug Administration] approval with a significant number of patients in need of care."

About Numinus Wellness Inc.

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental-health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model -- including psychedelic research, clinic care and practitioner training -- is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. Numinus is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.